Dakota15
Senior Member (Voting Rights)
Washington Post: 'Long covid patients are desperate for treatments. These trials may help.'
'Some trials are focusing on drugs that target the immune system, which is affected by different pathways to long covid.'
“Considering how far along we are and how tens of millions of people are suffering, we’ve done very little,” said Eric Topol
“It is absolutely not mysterious,” said Hannah Davis, co-founder of the Patient-Led Research Collaborative.
“There really needs to be a concerted, organized and well-funded biomarker discovery effort for this problem so that we can find a diagnostic test,” Peluso said.
Peluso, Ely and their collaborators are running a large double-blind, randomized clinical trial on a treatment seeking to turn off the immune “light switch that is creating this disease state, creating so much human suffering,” Ely said.
The trial, REVERSE-LC, will give patients baricitinib, which is an FDA-approved immunotherapeutic drug for treating other immune disorders such as rheumatoid arthritis and alopecia areata.
Another ongoing double-blind, randomized clinical trial, called ADDRESS-LC, will test a different, more specific immunomodulator called bezisterim for neurocognitive long covid.
'Some trials are focusing on drugs that target the immune system, which is affected by different pathways to long covid.'
“Considering how far along we are and how tens of millions of people are suffering, we’ve done very little,” said Eric Topol
“It is absolutely not mysterious,” said Hannah Davis, co-founder of the Patient-Led Research Collaborative.
“There really needs to be a concerted, organized and well-funded biomarker discovery effort for this problem so that we can find a diagnostic test,” Peluso said.
Peluso, Ely and their collaborators are running a large double-blind, randomized clinical trial on a treatment seeking to turn off the immune “light switch that is creating this disease state, creating so much human suffering,” Ely said.
The trial, REVERSE-LC, will give patients baricitinib, which is an FDA-approved immunotherapeutic drug for treating other immune disorders such as rheumatoid arthritis and alopecia areata.
Another ongoing double-blind, randomized clinical trial, called ADDRESS-LC, will test a different, more specific immunomodulator called bezisterim for neurocognitive long covid.